5 articles
Samsung Biologics launched a $2.1 billion rights offering to acquire PolyPeptide Group and expand Bio Campus II capacity. The investment targets peptide-based therapeutics and antibodies, aiming to re
Samsung Biologics launched a $1.8 billion bid for Swiss peptide maker PolyPeptide Group, expanding its contract manufacturing business into the fast-growing peptide market driven by GLP-1 drugs.
Samsung Biologics plans a $1.8 billion cash acquisition of Swiss drugmaker PolyPeptide to expand capabilities in peptide-based therapeutics like GLP-1 drugs. The offer includes a 6.1% premium and aims
Samsung Biologics completed a $280M acquisition of a GSK manufacturing facility in Maryland, marking the company's first manufacturing presence in the United States.
Samsung Biologics and Eli Lilly launched the Lilly Gateway Labs site at their South Korea Bio Campus II to support early-stage biotech companies.
ChemBrief